Various pharmacological and surgical interventions, including beta-blockers and amiodarone, are utilized to prevent and treat new-onset atrial fibrillation after cardiac surgery, though inconsistencies remain in risk stratification.
This review summarizes the pathophysiology, risk factors, and evidence-based prophylactic and therapeutic strategies for managing new-onset atrial fibrillation after cardiac surgery.
PURPOSE OF REVIEW: An overview of recent literature regarding pathophysiology, risk factors, prophylaxis, and treatment of new-onset atrial fibrillation (AF) in post-cardiac surgical patients. RECENT FINDINGS: AF is the most frequent adverse event after cardiac surgery with significant associated morbidity, mortality, and financial cost. Its causes are multifactorial, and models to stratify patients into risk categories are progressing but a consistent, evidence-based system has not yet been developed. Pharmacologic and surgical interventions to prevent and treat this complication have been an area of ongoing research and recent societal guidelines reflect this. SUMMARY: Inconsistencies remain surrounding how to best identify higher-risk AF patients, which interventions should be used to prevent and treat AF, and which patient groups should receive these interventions. The evidence for these available strategies and their place in contemporary guidelines are summarized.
Burrage et al. (Wed,) conducted a review in New-onset atrial fibrillation after cardiac surgery (AFACS). Pharmacological and surgical prophylactic and treatment strategies was evaluated. Various pharmacological and surgical interventions, including beta-blockers and amiodarone, are utilized to prevent and treat new-onset atrial fibrillation after cardiac surgery, though inconsistencies remain in risk stratification.